Aristolochic acid-associated cancers: a public health risk in need of global action.

Kumar, V., Poonam, Prasad, A. K. & Parmar, V. S. Naturally occurring aristolactams, aristolochic acids and dioxoaporphines and their biological activities. Nat. Product. Rep. 20, 565–583 (2003).

doi: 10.1039/b303648k

Han, J., Xian, Z., Zhang, Y., Liu, J. & Liang, A. Systematic overview of aristolochic acids: nephrotoxicity, carcinogenicity, and underlying mechanisms. Front. Pharmacol. 10, 648 (2019).

pubmed: 31244661 pmcid: 6580798 doi: 10.3389/fphar.2019.00648

Michl, J. et al. LC-MS- and

doi: 10.1021/acs.jnatprod.5b00556

Michl, J., Bello, O., Kite, G. C., Simmonds, M. S. J. & Heinrich, M. Medicinally used Asarum species: high-resolution LC-MS analysis of aristolochic acid analogs and in vitro toxicity screening in HK-2 cells. Front. Pharmacol. https://doi.org/10.3389/fphar.2017.00215 (2017).

doi: 10.3389/fphar.2017.00215 pubmed: 28588481 pmcid: 5439001

Scarborough, J. & Fernandes, A. Ancient medicinal use of Aristolochia: Birthwort’s tradition and toxicity. Pharm. Hist. 53, 3–21 (2011).

pubmed: 22702021

Tomlinson, T., Fernandes, A. & Grollman, A. P. Aristolochia herbs and iatrogenic disease: the case of Portland’s powders. Yale J. Biol. Med. 93, 355–363 (2020).

pubmed: 32607094 pmcid: 7309663

Grollman, A. P., Scarborough, J. & Jelaković, B. In: Advances in Molecular Toxicology Vol. 3 211–227 (Elsevier, 2009).

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Pharmaceuticals. Volume 100A. A review of human carcinogens. IARC Monogr. Eval. Carcinog. Risks Hum. 100, 1–401 (2012). In this volume of the IARC Monographs, the Working Group on the Evaluation of Carcinogenic Risks to Humans conducts a re-evaluation of AA and determines that the evidence available warrants its classification as a group 1 carcinogen.

pmcid: 4781577

Gold, L. S. & Slone, T. H. Aristolochic acid, an herbal carcinogen, sold on the web after FDA alert. N. Engl. J. Med. 349, 1576–1577 (2003).

pubmed: 14561805 doi: 10.1056/NEJM200310163491619

Arlt, V. M., Stiborova, M. & Schmeiser, H. H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17, 265–277 (2002).

pubmed: 12110620 doi: 10.1093/mutage/17.4.265

Ng, A. W. et al. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Sci. Transl. Med. 9, eaan6446 (2017). This study reports that an alarmingly high proportion (78%) of HCCs from patients treated in Taiwan harboured the AA mutational signature, and was among the first to examine the disparities in the occurrence of the AA mutational signature between patients with HCC in different countries.

pubmed: 29046434 doi: 10.1126/scitranslmed.aan6446

Martena, M. J. et al. Enforcement of the ban on aristolochic acids in Chinese traditional herbal preparations on the Dutch market. Anal. Bioanal. Chem. 389, 263–275 (2007).

pubmed: 17486320 doi: 10.1007/s00216-007-1310-3

Debelle, F. D., Vanherweghem, J.-L. & Nortier, J. L. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 74, 158–169 (2008).

pubmed: 18418355 doi: 10.1038/ki.2008.129

Wu, L. et al. An integrated system for identifying the hidden assassins in traditional medicines containing aristolochic acids. Sci. Rep. 5, 11318 (2015).

pubmed: 26270958 pmcid: 4535178 doi: 10.1038/srep11318

Zhang, H. M. et al. Recognition of the toxicity of aristolochic acid. J. Clin. Pharm. Ther. 44, 157–162 (2019).

pubmed: 30548302 doi: 10.1111/jcpt.12789

Vaclavik, L., Krynitsky, A. J. & Rader, J. I. Quantification of aristolochic acids I and II in herbal dietary supplements by ultra-high-performance liquid chromatography–multistage fragmentation mass spectrometry. Food Addit. Contam. Part. A Chem. Anal. Control. Expo. Risk Assess. 31, 784–791 (2014).

pubmed: 24512293 doi: 10.1080/19440049.2014.892215

Schaneberg, B. T. & Khan, I. A. Analysis of products suspected of containing Aristolochia or Asarum species. J. Ethnopharmacol. 94, 245–249 (2004).

pubmed: 15325726 doi: 10.1016/j.jep.2004.06.010

Cachet, X. et al. Detection of aristolochic acids I and II in “Chiniy-trèf”, a traditional medicinal preparation containing caterpillars feeding on Aristolochia trilobata L. in Martinique, French West Indies. Toxicon https://doi.org/10.1016/j.toxicon.2016.02.013 (2016).

doi: 10.1016/j.toxicon.2016.02.013 pubmed: 26879332

Riffault-Valois, L. et al. Health risk associated with the oral consumption of “Chiniy-tref”, a traditional medicinal preparation used in Martinique (French West Indies): qualitative and quantitative analyses of aristolochic acids contained therein. Toxicon 172, 53–60 (2019).

pubmed: 31704310 doi: 10.1016/j.toxicon.2019.10.241

Ioset, J. R., Raoelison, G. E. & Hostettmann, K. Detection of aristolochic acid in Chinese phytomedicines and dietary supplements used as slimming regimens. Food Chem. Toxicol. 41, 29–36 (2003).

pubmed: 12453725 doi: 10.1016/S0278-6915(02)00219-3

Cheung, T. P., Xue, C., Leung, K., Chan, K. & Li, C. G. Aristolochic acids detected in some raw Chinese medicinal herbs and manufactured herbal products — a consequence of inappropriate nomenclature and imprecise labelling? Clin. Toxicol. 44, 371–378 (2006).

doi: 10.1080/15563650600671712

Abdullah, R., Diaz, L. N., Wesseling, S. & Rietjens, I. M. C. M. Risk assessment of plant food supplements and other herbal products containing aristolochic acids using the margin of exposure (MOE) approach. Food Addit. Contam. Part. A 34, 135–144 (2017).

Liu, J., Liu, Y., Wu, Y., Dai, Z. & Ma, S. Rapid analysis of aristolochic acid analogues in traditional Chinese patent medicine by LC-MS/MS. J. Anal. Methods Chem. Anal. Control Expo. Risk Assess. 2020, 8823596 (2020).

Michl, J. et al. Is aristolochic acid nephropathy a widespread problem in developing countries?: a case study of Aristolochia indica L. in Bangladesh using an ethnobotanical–phytochemical approach. J. Ethnopharmacol. 149, 235–244 (2013).

pubmed: 23806867 doi: 10.1016/j.jep.2013.06.028

Maggini, V., Menniti-Ippolito, F. & Firenzuoli, F. Aristolochia, a nephrotoxic herb, still surfs on the Web, 15 years later. Intern. Emerg. Med. 13, 811–813 (2018).

pubmed: 29498013 doi: 10.1007/s11739-018-1813-2

Shibutani, S. et al. Selective toxicity of aristolochic acids I and II. Drug Metab. Dispos. 35, 1217–1222 (2007).

pubmed: 17392392 doi: 10.1124/dmd.107.014688

Kucab, J. E. et al. A compendium of mutational signatures of environmental agents. Cell 177, 821–836.e16 (2019).

pubmed: 30982602 pmcid: 6506336 doi: 10.1016/j.cell.2019.03.001

Wu, S. Two cases of acute renal failure caused by mutong. Jiang Xi Zhong Yi 10, 12–14 (1964).

Hong, Y., Huang, Y. & Wang, Y. Over-dose of mutong causes renal failure and death. Zhe Jiang Zhong Yi Za Zhi 8, 32 (1965).

Zhou, F., Lu, H. & Nie, C. Toxicity of mutong causes acute renal failure. Zhonghua Shenzanbing Za Zhi 4, 223–224 (1988).

Poon, W.-T., Lai, C.-K. & Chan, A. Y.-W. Aristolochic acid nephropathy: the Hong Kong perspective. Hong. Kong J. Nephrol. 9, 7–14 (2007).

doi: 10.1016/S1561-5413(07)60003-9

Jackson, L., Kofman, S., Weiss, A. & Brodovsky, H. Aristolochic acid (Nsc-50413): phase I clinical study. Cancer Chemother. Rep. 42, 35–37 (1964).

pubmed: 14226128

Kupchan, S. M. & Doskotch, R. W. Tumor inhibitors. I. Aristolochic acid, the active principle of Aristolochia indica. J. Med. Pharm. Chem. 91, 657–659 (1962).

pubmed: 14056399 doi: 10.1021/jm01238a029

Ivić, M. Etiology of endemic nephropathy. Lijec. Vjesn. 91, 1273–1281 (1969).

pubmed: 5200813

Vanherweghem, J.-L. et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341, 387–391 (1993).

pubmed: 8094166 doi: 10.1016/0140-6736(93)92984-2

Vanherweghem, J.-L. Misuse of herbal remedies: the case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy). J. Altern. Complement. Med. 4, 9–13 (1998).

pubmed: 9553830 doi: 10.1089/acm.1998.4.1-9

Depierreux, M., Van Damme, B., Houte, K. V. & Vanherweghem, J. L. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am. J. Kidney Dis. 24, 172–180 (1994).

pubmed: 8048421 doi: 10.1016/S0272-6386(12)80178-8

Cosyns, J. P. et al. Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int. 45, 1680–1688 (1994). The authors examine the renal cortex specimens from individuals affected by the Belgian outbreak of AAN and report the first link connecting AAN to endemic nephropathy.

pubmed: 7933816 doi: 10.1038/ki.1994.220

Nortier, J. L. et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 342, 1686–1692 (2000). This study reports that patients with AAN face a high risk of developing urothelial carcinoma.

pubmed: 10841870 doi: 10.1056/NEJM200006083422301

Cosyns, J.-P., Jadoul, M., Squifflet, J.-P., Wese, F.-X. & van Ypersele de Strihou, C. Urothelial lesions in Chinese-herb nephropathy. Am. J. Kidney Dis. 33, 1011–1017 (1999).

pubmed: 10352187 doi: 10.1016/S0272-6386(99)70136-8

Lemy, A. et al. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am. J. Kidney Dis. 51, 471–477 (2008).

pubmed: 18295063 doi: 10.1053/j.ajkd.2007.11.015

Sun, M. et al. Analysis of potential risk factors for cancer incidence in patients with aristolochic acid nephropathy from Wenzhou, China. Ren. Fail. 37, 209–213 (2015).

pubmed: 25540870 doi: 10.3109/0886022X.2014.990347

Yang, C.-S., Lin, C.-H., Chang, S.-H. & Hsu, H.-C. Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. Am. J. Kidney Dis. 35, 313–318 (2000).

pubmed: 10676733 doi: 10.1016/S0272-6386(00)70343-X

Wu, Y., Liu, Z., Hu, W. & Li, L. Mast cell infiltration associated with tubulointerstitial fibrosis in chronic aristolochic acid nephropathy. Hum. Exp. Toxicol. 24, 41–47 (2005).

pubmed: 15850277 doi: 10.1191/0960327105ht502oa

Zhang, J., Zhang, L., Wang, W. & Wang, H. Association between aristolochic acid and CKD: a cross-sectional survey in China. Am. J. Kidney Dis. 61, 918–922 (2013).

pubmed: 23466214 doi: 10.1053/j.ajkd.2012.12.027

Pena, J. M., Borras, M., Ramos, J. & Montoliu, J. Rapidly progressive interstitial renal fibrosis due to a chronic intake of a herb (Aristolochia pistolochia) infusion. Nephrol. Dial. Transpl. 11, 1359–1360 (1996).

doi: 10.1093/ndt/11.7.1359

Stengel, B. & Jones, E. End-stage renal insufficiency associated with Chinese herbal consumption in France [French]. Nephrologie 19, 15–20 (1998).

pubmed: 9551447

Krumme, B., Endmeir, R., Vanhaelen, M. & Walb, D. Reversible Fanconi syndrome after ingestion of a Chinese herbal ‘remedy’ containing aristolochic acid. Nephrol. Dial. Transpl. 16, 400–402 (2001).

doi: 10.1093/ndt/16.2.400

Kazama, I. et al. Adult onset Fanconi syndrome: extensive tubulo-interstitial lesions and glomerulopathy in the early stage of Chinese herbs nephropathy. Clin. Exp. Nephrol. 8, 283–287 (2004).

pubmed: 15480910 doi: 10.1007/s10157-004-0296-9

Meyer, M. M., Chen, T. P. & Bennett, W. M. Chinese herb nephropathy. Proc. (Bayl. Univ. Med. Cent.) 13, 334–337 (2000).

Lee, S. et al. Fanconi’s syndrome and subsequent progressive renal failure caused by a Chinese herb containing aristolochic acid. Nephrology 9, 126–129 (2004).

pubmed: 15189173 doi: 10.1111/j.1440-1797.2003.00232.x

Schmeiser, H. H., Bieler, C. A., Wiessler, M., de Strihou, C. V. Y. & Cosyns, J.-P. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 56, 2025–2028 (1996). This study establishes the presence of AL–DNA adducts in renal tissue obtained from patients of the Belgian outbreak of AAN, implicating AA as the agent responsible for the observed nephropathy.

pubmed: 8616845

Stiborová, M., Frei, E., Breuer, A., Bieler, C. A. & Schmeiser, H. H. Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy. Exp. Toxicol. Pathol. 51, 421–427 (1999).

pubmed: 10445409 doi: 10.1016/S0940-2993(99)80033-5

Lord, G. M. et al. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358, 1515–1516 (2001).

pubmed: 11705569 doi: 10.1016/S0140-6736(01)06576-X

Bieler, C. A. et al.

pubmed: 9163697 doi: 10.1093/carcin/18.5.1063

Lo, S. H. et al. Detection of Herba Aristolochia Mollissemae in a patient with unexplained nephropathy. Am. J. Kidney Dis. 45, 407–410 (2005).

pubmed: 15685520 doi: 10.1053/j.ajkd.2004.09.019

Chen, C.-H. et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc. Natl Acad. Sci. USA 109, 8241–8246 (2012). This breakthrough molecular epidemiology study in East Asia establishes the significant contribution of exposure to AA to the high incidence of UTUC, using the characteristic molecular markers of exposure and its impact.

pubmed: 22493262 pmcid: 3361449 doi: 10.1073/pnas.1119920109

Yun, B. H. et al. Biomonitoring of aristolactam–DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry. Chem. Res. Toxicol. 25, 1119–1131 (2012).

pubmed: 22515372 pmcid: 3536064 doi: 10.1021/tx3000889

Lord, G. M. et al. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am. J. Kidney Dis. 43, e18.11–e18.17 (2004).

doi: 10.1053/j.ajkd.2003.11.024

Chen, H. Y., Ma, B.-Y., Grant, A. & Lampert, N. Time to abandon the term “Chinese herbs nephropathy”. Kidney Int. 60, 2039–2040 (2001).

pubmed: 11703630 doi: 10.1046/j.1523-1755.2001.00034.x

Gillerot, G. et al. Aristolochic acid nephropathy in a Chinese patient: time to abandon the term “Chinese herbs nephropathy”? Am. J. Kidney Dis. 38, E26 (2001).

pubmed: 11684578 doi: 10.1053/ajkd.2001.28624

Grollman, A. P. et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl Acad. Sci. USA 104, 12129 (2007). This molecular epidemiology study establishes dietary exposure to AA from environmental sources as a significant risk factor for BEN and associated urothelial carcinomas.

pubmed: 17620607 pmcid: 1913550 doi: 10.1073/pnas.0701248104

Jelaković, B. et al. Aristolactam–DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int. 81, 559–567 (2012). This work describes the occurrence of AL–DNA adducts and the TP53 AA mutational spectrum in the UTUC of patients who resided in the endemic region.

pubmed: 22071594 doi: 10.1038/ki.2011.371

Arlt, V. M. et al. Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int. J. Cancer 101, 500–502 (2002).

pubmed: 12216081 doi: 10.1002/ijc.10602

Batuman, V. Fifty years of Balkan endemic nephropathy: daunting questions, elusive answers. Kidney Int. 69, 644–646 (2006).

pubmed: 16467889 doi: 10.1038/sj.ki.5000231

Hranjec, T. et al. Endemic nephropathy: the case for chronic poisoning by Aristolochia. Croat. Med. J. 46, 116–125 (2005).

pubmed: 15726685

Hsieh, S.-C., Lin, I.-H., Tseng, W.-L., Lee, C.-H. & Wang, J.-D. Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003. Chin. Med. 3, 1–6 (2008).

doi: 10.1186/1749-8546-3-13

Lai, M.-N. et al. Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case–control study. Am. J. Kidney Dis. 55, 507–518 (2010).

pubmed: 20116155 doi: 10.1053/j.ajkd.2009.10.055

Lai, M.-N., Wang, S.-M., Chen, P.-C., Chen, Y.-Y. & Wang, J.-D. Population-based case–control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J. Natl Cancer Inst. 102, 179–186 (2010). This case–control study examines the association between prescription of AA-containing herbal products and urinary tract cancer in Taiwan, reporting that consumption of AA-containing herbal products is associated with an increased risk of urinary tract cancer.

pubmed: 20026811 pmcid: 2815723 doi: 10.1093/jnci/djp467

Hoang, M. L. et al. Aristolochic acid in the etiology of renal cell carcinoma. Cancer Epidemiol. Prev. Biomark. 25, 1600–1608 (2016).

doi: 10.1158/1055-9965.EPI-16-0219

Yang, H.-y, Wang, J.-D., Lo, T.-C. & Chen, P.-C. Increased mortality risk for cancers of the kidney and other urinary organs among Chinese herbalists. J. Epidemiol. Jpn. Epidemiol. Assoc. 19, 17–23 (2009).

doi: 10.2188/jea.JE20080035

Yang, H.-Y., Wang, J.-D., Lo, T.-C. & Chen, P.-C. Increased risks of upper tract urothelial carcinoma in male and female Chinese herbalists. J. Formos. Med. Assoc. 110, 161–168 (2011). This study reports that herbalists in Taiwan had a significantly higher risk of developing upper tract urothelial, renal and bladder cancers.

pubmed: 21497279 doi: 10.1016/S0929-6646(11)60026-0

Yang, H.-Y., Wang, J.-D., Lo, T.-C. & Chen, P.-C. Occupational kidney disease among Chinese herbalists exposed to herbs containing aristolochic acids. Occup. Environ. Med. 68, 286–290 (2011).

pubmed: 20935286 doi: 10.1136/oem.2010.058594

Yang, H.-Y., Wang, J.-D., Lo, T.-C. & Chen, P.-C. Occupational exposure to herbs containing aristolochic acids increases the risk of urothelial carcinoma in Chinese herbalists. J. Urol. 189, 48–52 (2013). Following up on a previous study (ref. 73), the authors determine that having processed, sold or dispensed herbs containing fangchi significantly increases the risk of developing urothelial carcinoma in Chinese herbalists.

pubmed: 23164394 doi: 10.1016/j.juro.2012.08.090

Chen, C.-J. et al. Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. Int. J. Cancer 143, 1578–1587 (2018). This study reports a significant dose–response relationship between the consumption of AA-containing herbs and the risk of developing HCC among patients infected with HBV.

pubmed: 29667191 doi: 10.1002/ijc.31544

Chen, C. J. et al. Herbal medicine containing aristolochic acid and the risk of primary liver cancer in patients with hepatitis C virus infection. Cancer Epidemiol. Biomark. Prev. 28, 1876–1883 (2019). This study reports a significant dose–response relationship between the consumption of AA-containing herbs and the risk of developing primary liver cancers among patients infected with HCV.

doi: 10.1158/1055-9965.EPI-19-0023

Chen, C. J. et al. Aristolochic acid and the risk of cancers in patients with type 2 diabetes: nationwide population-based cohort study. Phytomedicine 99, 154023 (2022). This study reports that the use of AA-containing herbs is associated with a significantly higher risk of developing liver, colorectum, kidney, bladder, prostate, pelvis and ureter cancers in patients with diabetes.

pubmed: 35276591 doi: 10.1016/j.phymed.2022.154023

Hollstein, M., Moriya, M., Grollman, A. P. & Olivier, M. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Mutat. Res. 753, 41–49 (2013).

pubmed: 23422071 pmcid: 3689860 doi: 10.1016/j.mrrev.2013.02.003

Mengs, U. Tumour induction in mice following exposure to aristolochic acid. Arch. Toxicol. 61, 504–505 (1988).

pubmed: 3190449 doi: 10.1007/BF00293699

Mengs, U., Lang, W. & Poch, J. A. The carcinogenic action of aristolochic acid in rats. Arch. Toxicol. 51, 107–119 (1982).

doi: 10.1007/BF00302751

Mengs, U. On the histopathogenesis of rat forestomach carcinoma caused by aristolochic acid. Arch. Toxicol. 52, 209–220 (1983).

pubmed: 6860143 doi: 10.1007/BF00333900

Hwang, M. S. et al. Subchronic toxicity studies of the aqueous extract of Aristolochiae fructus in Sprague-Dawley rats. J. Toxicol. Env. Health A 69, 2157–2165 (2006).

doi: 10.1080/15287390600747965

Schmeiser, H. H. et al. Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res. 50, 5464–5469 (1990).

pubmed: 2201437

Lu, Z. N. et al. The mutational features of aristolochic acid–induced mouse and human liver cancers. Hepatology 71, 929–942 (2020).

pubmed: 31692012 doi: 10.1002/hep.30863

Jadot, I., Declèves, A.-E., Nortier, J. & Caron, N. An integrated view of aristolochic acid nephropathy: update of the literature. Int. J. Mol. Sci. 18, 297 (2017).

pmcid: 5343833 doi: 10.3390/ijms18020297

National Toxicology Program. Aristolochic acids. Rep. Carcinog. 12, 45–49 (2011).

Chang, S. Y. et al. Human liver–kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity. JCI Insight https://doi.org/10.1172/jci.insight.95978 (2017).

doi: 10.1172/jci.insight.95978 pubmed: 29202460 pmcid: 5752380

Hashimoto, K. et al. Sulfotransferase-1A1-dependent bioactivation of aristolochic acid I and N-hydroxyaristolactam I in human cells. Carcinogenesis 37, 647–655 (2016).

pubmed: 27207664 pmcid: 4936383 doi: 10.1093/carcin/bgw045

Sidorenko, V. S. Biotransformation and toxicities of aristolochic acids. Adv. Exp. Med. Biol. 1241, 139–166 (2020).

pubmed: 32383120 doi: 10.1007/978-3-030-41283-8_9

Sidorenko, V. S. et al. Bioactivation of the human carcinogen aristolochic acid. Carcinogenesis 35, 1814–1822 (2014).

pubmed: 24743514 pmcid: 4123648 doi: 10.1093/carcin/bgu095

Stiborova, M., Martinek, V., Frei, E., Arlt, V. M. & Schmeiser, H. H. Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer. Curr. Drug Metab. 14, 695–705 (2013).

pubmed: 23701164 doi: 10.2174/1389200211314060006

Okuno, Y. et al. Bioactivation mechanisms of N-hydroxyaristolactams: nitroreduction metabolites of aristolochic acids. Environ. Mol. Mutagen. 60, 792–806 (2019).

pubmed: 31374128 pmcid: 6899766 doi: 10.1002/em.22321

Arlt, V. M. et al. Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitrobenzanthrone. Arch. Toxicol. 91, 1957–1975 (2017).

pubmed: 27557898 doi: 10.1007/s00204-016-1808-6

Pfau, W., Schmeiser, H. H. & Wiessler, M. Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis 11, 313–319 (1990).

pubmed: 2302759 doi: 10.1093/carcin/11.2.313

Attaluri, S. et al. DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells. Nucleic Acids Res. 38, 339–352 (2010).

pubmed: 19854934 doi: 10.1093/nar/gkp815

Broschard, T. H., Wiessler, M., von der Lieth, C.-W. & Schmeiser, H. H. Translesional synthesis on DNA templates containing site-specifically placed deoxyadenosine and deoxyguanosine adducts formed by the plant carcinogen aristolochic acid. Carcinogenesis 15, 2331–2340 (1994).

pubmed: 7955074 doi: 10.1093/carcin/15.10.2331

Schmeiser, H. H. et al. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int. J. Cancer 135, 502–507 (2014).

pubmed: 24921086 doi: 10.1002/ijc.28681

Liu, Y., Chan, C. K., Jin, L., Wong, S. K. & Chan, W. Quantitation of DNA adducts in target and nontarget organs of aristolochic acid I-exposed rats: correlating DNA adduct levels with organotropic activities. Chem. Res. Toxicol. 32, 397–399 (2019).

pubmed: 30604963 doi: 10.1021/acs.chemrestox.8b00359

Fernando, R. C., Schmeiser, H. H., Scherf, H. R. & Wiessler, M. Formation and persistence of specific purine DNA adducts by

Sidorenko, V. S. et al. Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam–DNA adducts. Nucleic Acids Res. 40, 2494–2505 (2012).

pubmed: 22121226 doi: 10.1093/nar/gkr1095

Lukin, M., Zaliznyak, T., Johnson, F. & de los Santos, C. Structure and stability of DNA containing an aristolactam II–dA lesion: implications for the NER recognition of bulky adducts. Nucleic Acids Res. 40, 2759–2770 (2012).

pubmed: 22121223 doi: 10.1093/nar/gkr1094

Hashimoto, K., Bonala, R., Johnson, F., Grollman, A. P. & Moriya, M. Y-family DNA polymerase-independent gap-filling translesion synthesis across aristolochic acid-derived adenine adducts in mouse cells. DNA Repair. 46, 55–60 (2016).

pubmed: 27497692 pmcid: 5048550 doi: 10.1016/j.dnarep.2016.07.003

Poon, S. L. et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci. Transl. Med. 5, 197ra101–197ra101 (2013). This study provides one of the first descriptions of the AA mutational signature on a genome-wide scale in mice and humans.

pubmed: 23926199 doi: 10.1126/scitranslmed.3006086

Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

pubmed: 23945592 pmcid: 3776390 doi: 10.1038/nature12477

Moriya, M. et al. TP53 mutational signature for aristolochic acid: an environmental carcinogen. Int. J. Cancer 129, 1532–1536 (2011).

pubmed: 21413016 doi: 10.1002/ijc.26077

Hoang, M. L. et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci. Transl. Med. 5, 197ra102–197ra102 (2013). This study describes the AA mutational signature in UTUC in individuals with documented exposure to AA, illustrating the mutagenicity of AA in humans and providing one of the first descriptions of the AA mutational signature on a genome-wide scale.

pubmed: 23926200 pmcid: 3973132 doi: 10.1126/scitranslmed.3006200

Rosenquist, T. A. & Grollman, A. P. Mutational signature of aristolochic acid: clue to the recognition of a global disease. DNA Repair. 44, 205–211 (2016).

pubmed: 27237586 doi: 10.1016/j.dnarep.2016.05.027

Castells, X. et al. Low-coverage exome sequencing screen in formalin-fixed paraffin-embedded tumors reveals evidence of exposure to carcinogenic aristolochic acid. Cancer Epidemiol. Prev. Biomark. 24, 1873–1881 (2015). This study describes a protocol for conducting low-coverage whole-exome sequencing that can reliably detect the AA mutational signature, among other signatures, in archival FFPE urothelial tumours.

doi: 10.1158/1055-9965.EPI-15-0553

Lu, H. et al. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma. Theranostics 10, 4323–4333 (2020). The authors conduct whole-genome sequencing on 90 upper tract urothelial cancers from patients residing in China that were not preselected for documented AA consumption, and report that 27 harboured the AA mutational signature and that the mutational signature may be detected in urinary cell-free DNA.

pubmed: 32292497 pmcid: 7150494 doi: 10.7150/thno.43251

Poon, S. L. et al. Mutation signatures implicate aristolochic acid in bladder cancer development. Genome Med. 7, 1–10 (2015).

doi: 10.1186/s13073-015-0161-3

Lai, H.-Y. et al. High level of aristolochic acid detected with a unique genomic landscape predicts early UTUC onset after renal transplantation in Taiwan. Front. Oncol. 11, 828314–828314 (2022).

pubmed: 35071023 pmcid: 8770835 doi: 10.3389/fonc.2021.828314

Scelo, G. et al. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat. Commun. 5, 1–13 (2014). This study presents whole-genome sequences of ccRCCs from four European countries, identifying the AA mutational signature in cancers originating from patients from Romania but outside the previously reported endemic region.

doi: 10.1038/ncomms6135

Turesky, R. J. et al. Aristolochic acid exposure in Romania and implications for renal cell carcinoma. Br. J. Cancer 114, 76–80 (2016). Following up on the earlier report by Scelo et al. (2014), the authors detect the AL–DNA adduct in non-tumour renal tissue from the AA-associated Romanian RCC cases reported by Scelo et al., concluding that AA exposure occurs and is responsible for causing AA-associated diseases in Europe outside the previously reported endemic region.

pubmed: 26657656 doi: 10.1038/bjc.2015.402

Jelaković, B. et al. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid. Int. J. Cancer 136, 2967–2972 (2015).

pubmed: 25403517 doi: 10.1002/ijc.29338

Letouzé, E. et al. Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nat. Commun. 8, 1315 (2017).

pubmed: 29101368 pmcid: 5670220 doi: 10.1038/s41467-017-01358-x

Lin, J. et al. Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics 11, 4585–4598 (2021).

pubmed: 33754015 pmcid: 7978308 doi: 10.7150/thno.56539

Zou, S. et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat. Commun. 5, 5696 (2014).

pubmed: 25526346 doi: 10.1038/ncomms6696

Moody, S. et al. Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence. Nat. Genet. 53, 1553–1563 (2021).

pubmed: 34663923 doi: 10.1038/s41588-021-00928-6

Cui, Y. et al. Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma. Cell Res. 30, 902–913 (2020).

pubmed: 32398863 pmcid: 7608103 doi: 10.1038/s41422-020-0333-6

Du, Y. et al. Mutagenic factors and complex clonal relationship of multifocal urothelial cell carcinoma. Eur. Urol. 71, 841–843 (2017).

pubmed: 27743758 doi: 10.1016/j.eururo.2016.09.046

Guo, G. et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat. Genet. 45, 1459–1463 (2013).

pubmed: 24121792 pmcid: 7512009 doi: 10.1038/ng.2798

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014).

doi: 10.1038/nature12965

Li, R. et al. Macroscopic somatic clonal expansion in morphologically normal human urothelium. Science 370, 82–89 (2020).

pubmed: 33004515 doi: 10.1126/science.aba7300

Lawson, A. R. J. et al. Extensive heterogeneity in somatic mutation and selection in the human bladder. Science 370, 75–82 (2020).

pubmed: 33004514 doi: 10.1126/science.aba8347

Hoang, M. L. et al. Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. Proc. Natl Acad. Sci. USA 113, 9846 (2016).

pubmed: 27528664 pmcid: 5024639 doi: 10.1073/pnas.1607794113

Sung, W. K. et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet. 44, 765–769 (2012).

pubmed: 22634754 doi: 10.1038/ng.2295

Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327–1341.e23 (2017).

doi: 10.1016/j.cell.2017.05.046

Candia, J. et al. The genomic landscape of Mongolian hepatocellular carcinoma. Nat. Commun. 11, 4383 (2020).

pubmed: 32873799 pmcid: 7462863 doi: 10.1038/s41467-020-18186-1

Li, R. et al. A body map of somatic mutagenesis in morphologically normal human tissues. Nature 597, 398–403 (2021).

pubmed: 34433965 doi: 10.1038/s41586-021-03836-1

Zhai, W. et al. Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study. Nat. Sci. Rev. 9, nwab192 (2021).

doi: 10.1093/nsr/nwab192

Lim, A. H. et al. Rare occurrence of aristolochic acid mutational signatures in oro-gastrointestinal tract cancers. Cancers 14, 576 (2022).

pubmed: 35158844 pmcid: 8833562 doi: 10.3390/cancers14030576

Nik-Zainal, S. et al. The genome as a record of environmental exposure. Mutagenesis 30, 763–770 (2015).

pubmed: 26443852 pmcid: 4637815

Olivier, M. et al. Modelling mutational landscapes of human cancers in vitro. Sci. Rep. 4, 1–9 (2014).

doi: 10.1038/srep04482

Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).

pubmed: 32025018 pmcid: 7054213 doi: 10.1038/s41586-020-1943-3

Blokzijl, F., Janssen, R., van Boxtel, R. & Cuppen, E. MutationalPatterns: comprehensive genome-wide analysis of mutational processes. Genome Med. 10, 33 (2018).

pubmed: 29695279 pmcid: 5922316 doi: 10.1186/s13073-018-0539-0

Islam, S. M. A. & Alexandrov, L. B. Bioinformatic methods to identify mutational signatures in cancer. Methods Mol. Biol. 2185, 447–473 (2021).

pubmed: 33165866 doi: 10.1007/978-1-0716-0810-4_28

Degasperi, A. et al. Substitution mutational signatures in whole-genome-sequenced cancers in the UK population. Science https://doi.org/10.1126/science.abl9283 (2022).

doi: 10.1126/science.abl9283 pubmed: 35949260 pmcid: 7613262

Karanović, S. et al. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure. Int. J. Cancer 150, 374–386 (2022).

pubmed: 34569060 doi: 10.1002/ijc.33827

Chen, C.-H. et al. Additive effects of arsenic and aristolochic acid in chemical carcinogenesis of upper urinary tract urothelium. Cancer Epidemiol. Biomark. Prev. 30, 317 (2021).

doi: 10.1158/1055-9965.EPI-20-1090

Zhang, M., Liu, H., Han, Y., Bai, L. & Yan, H. A review on the pharmacological properties, toxicological characteristics, pathogenic mechanism and analytical methods of aristolochic acids. Toxin Rev. 30, 1–10 (2020).

Chan, W., Lee, K.-C., Liu, N. & Cai, Z. A sensitivity enhanced high-performance liquid chromatography fluorescence method for the detection of nephrotoxic and carcinogenic aristolochic acid in herbal medicines. J. Chromatogr. A 1164, 113–119 (2007).

pubmed: 17631302 doi: 10.1016/j.chroma.2007.06.055

de Boer, H. J., Ichim, M. C. & Newmaster, S. G. DNA barcoding and pharmacovigilance of herbal medicines. Drug Saf. 38, 611–620 (2015).

pubmed: 26076652 doi: 10.1007/s40264-015-0306-8

Li, M. et al. Molecular identification and cytotoxicity study of herbal medicinal materials that are confused by Aristolochia herbs. Food Chem. 147, 332–339 (2014).

pubmed: 24206727 doi: 10.1016/j.foodchem.2013.09.146

Sgamma, T., Masiero, E., Mali, P., Mahat, M. & Slater, A. Sequence-specific detection of Aristolochia DNA — a simple test for contamination of herbal products. Front. Plant Sci. 9, 1828–1828 (2018).

pubmed: 30619401 pmcid: 6297175 doi: 10.3389/fpls.2018.01828

Dechbumroong, P., Aumnouypol, S., Denduangboripant, J. & Sukrong, S. DNA barcoding of Aristolochia plants and development of species-specific multiplex PCR to aid HPTLC in ascertainment of Aristolochia herbal materials. PloS ONE 13, e0202625 (2018).

pubmed: 30125304 pmcid: 6101415 doi: 10.1371/journal.pone.0202625

Wu, L. et al. Rapid identification of officinal Akebiae Caulis and its toxic adulterant Aristolochiae Manshuriensis Caulis (Aristolochia manshuriensis) by loop-mediated isothermal amplification. Front. Plant. Sci. 7, 887–887 (2016).

pubmed: 27379153 pmcid: 4913086 doi: 10.3389/fpls.2016.00887

Raclariu, A. C., Heinrich, M., Ichim, M. C. & de Boer, H. Benefits and limitations of DNA barcoding and metabarcoding in herbal product authentication. Phytochem. Anal. 29, 123–128 (2018).

pubmed: 28906059 doi: 10.1002/pca.2732

Bruni, I. et al. Identification of poisonous plants by DNA barcoding approach. Int. J. Leg. Med. 124, 595–603 (2010).

doi: 10.1007/s00414-010-0447-3

Yun, B. H., Bellamri, M., Rosenquist, T. A. & Turesky, R. J. Method for biomonitoring DNA adducts in exfoliated urinary cells by mass spectrometry. Anal. Chem. 90, 9943–9950 (2018).

pubmed: 30001485 pmcid: 6237078 doi: 10.1021/acs.analchem.8b02170

Guo, J. et al. Multiclass carcinogenic DNA adduct quantification in formalin-fixed paraffin-embedded tissues by ultraperformance liquid chromatography–tandem mass spectrometry. Anal. Chem. 88, 4780–4787 (2016).

pubmed: 27043225 pmcid: 4854775 doi: 10.1021/acs.analchem.6b00124

Yun, B. H. et al. Human formalin-fixed paraffin-embedded tissues: an untapped specimen for biomonitoring of carcinogen DNA adducts by mass spectrometry. Anal. Chem. 85, 4251–4258 (2013).

pubmed: 23550627 pmcid: 3904361 doi: 10.1021/ac400612x

Yun, B. H. et al. Formalin-fixed paraffin-embedded tissue as a source for quantitation of carcinogen DNA adducts: aristolochic acid as a prototype carcinogen. Carcinogenesis 35, 2055–2061 (2014).

pubmed: 24776219 pmcid: 4146416 doi: 10.1093/carcin/bgu101

Abascal, F. et al. Somatic mutation landscapes at single-molecule resolution. Nature 593, 405–410 (2021).

pubmed: 33911282 doi: 10.1038/s41586-021-03477-4

Kennedy, S. R. et al. Detecting ultralow-frequency mutations by duplex sequencing. Nat. Protoc. 9, 2586–2606 (2014).

pubmed: 25299156 pmcid: 4271547 doi: 10.1038/nprot.2014.170

Salk, J. J., Schmitt, M. W. & Loeb, L. A. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat. Rev. Genet. 19, 269–285 (2018).

pubmed: 29576615 pmcid: 6485430 doi: 10.1038/nrg.2017.117

Schmitt, M. W. et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl Acad. Sci. USA 109, 14508–14513 (2012).

pubmed: 22853953 pmcid: 3437896 doi: 10.1073/pnas.1208715109

Guo, L. et al. A novel and specific method for the determination of aristolochic acid-derived DNA adducts in exfoliated urothelial cells by using ultra performance liquid chromatography–triple quadrupole mass spectrometry. J. Chromatogr. B 879, 153–158 (2011).

doi: 10.1016/j.jchromb.2010.11.035

Yun, B. H. et al. New approaches for biomonitoring exposure to the human carcinogen aristolochic acid. Toxicol. Res. 4, 763–776 (2015).

doi: 10.1039/C5TX00052A

Leung, E. M. K. & Chan, W. Noninvasive measurement of aristolochic acid–DNA adducts in urine samples from aristolochic acid-treated rats by liquid chromatography coupled tandem mass spectrometry: evidence for DNA repair by nucleotide-excision repair mechanisms. Mutat. Res. Fund. Mol. Mech. Mutagen. 766–767, 1–6 (2014).

doi: 10.1016/j.mrfmmm.2014.05.004

Leung, E. M. K. & Chan, W. Quantification of aristolochic acid–RNA adducts in the urine of aristolochic acid-treated rats by liquid chromatography–tandem mass spectrometry. Chem. Res. Toxicol. 28, 567–569 (2015).

pubmed: 25715065 doi: 10.1021/acs.chemrestox.5b00021

Springer, S. U. et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. eLife 7, e32143 (2018).

pubmed: 29557778 pmcid: 5860864 doi: 10.7554/eLife.32143

Phillips, D. H. Mutational spectra and mutational signatures: insights into cancer aetiology and mechanisms of DNA damage and repair. DNA Repair. 71, 6–11 (2018).

pubmed: 30236628 pmcid: 6219445 doi: 10.1016/j.dnarep.2018.08.003

Zhivagui, M. et al. Experimental and pan-cancer genome analyses reveal widespread contribution of acrylamide exposure to carcinogenesis in humans. Genome Res. 29, 521–531 (2019).

pubmed: 30846532 pmcid: 6442384 doi: 10.1101/gr.242453.118

Nassar, D., Latil, M., Boeckx, B., Lambrechts, D. & Blanpain, C. Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. Nat. Med. 21, 946–954 (2015).

pubmed: 26168291 doi: 10.1038/nm.3878

Westcott, P. M. et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517, 489–492 (2015).

pubmed: 25363767 doi: 10.1038/nature13898

McCreery, M. Q. et al. Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers. Nat. Med. 21, 1514–1520 (2015).

pubmed: 26523969 pmcid: 5094808 doi: 10.1038/nm.3979

Ng, S. W. K. et al. Convergent somatic mutations in metabolism genes in chronic liver disease. Nature 598, 473–478 (2021).

pubmed: 34646017 doi: 10.1038/s41586-021-03974-6

Popovska-Jankovic, K. et al. microRNA profiling in patients with upper tract urothelial carcinoma associated with Balkan endemic nephropathy. BioMed. Res. Int. 2016, 7450461 (2016).

pubmed: 27218105 pmcid: 4863087 doi: 10.1155/2016/7450461

Tao, L. et al. Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo. Mol. Med. Rep. 12, 6533–6546 (2015).

pubmed: 26397152 pmcid: 4626193 doi: 10.3892/mmr.2015.4330

Wang, S.-M. et al. Increased upper and lower tract urothelial carcinoma in patients with end-stage renal disease: a nationwide cohort study in Taiwan during 1997–2008. BioMed. Res. Int. 2014, 149750–149750 (2014).

pubmed: 25025033 pmcid: 4084494

Jhuang, J.-R., Chiang, C.-J., Su, S.-Y., Yang, Y.-W. & Lee, W.-C. Reduction in the incidence of urological cancers after the Ban on chinese Herbal products containing aristolochic acid: an interrupted time-series analysis. Sci. Rep. 9, 1–8 (2019). This study provides the first look into disease trends following the prohibition of AA-containing herbal products in Taiwan, showing a possible reduction in incidence rates of bladder cancer, carcinomas of the renal pelvis and other urinary organs consequent to the implementation of these prohibitions.

doi: 10.1038/s41598-019-56394-y

Fan, Y., Li, Z. & Xi, J. Recent developments in detoxication techniques for aristolochic acid-containing traditional Chinese medicines. RSC Adv. 10, 1410–1425 (2020).

pubmed: 35494720 pmcid: 9048270 doi: 10.1039/C9RA08327H

Rebhan, K., Ertl, I. E., Shariat, S. F., Grollman, A. P. & Rosenquist, T. Aristolochic acid and its effect on different cancers in uro-oncology. Curr. Opin. Urol. 30, 689–695 (2020).

pubmed: 32701724

Stiborová, M., Arlt, V. M. & Schmeiser, H. H. Balkan endemic nephropathy: an update on its aetiology. Arch. Toxicol. 90, 2595–2615 (2016).

pubmed: 27538407 pmcid: 5065591 doi: 10.1007/s00204-016-1819-3

Chan, C.-K., Liu, Y., Pavlović, N. M. & Chan, W. Aristolochic acids: newly identified exposure pathways of this class of environmental and food-borne contaminants and its potential link to chronic kidney diseases. Toxics 7, 14 (2019).

pmcid: 6468885 doi: 10.3390/toxics7010014

Heinrich, M., Chan, J., Wanke, S., Neinhuis, C. & Simmonds, M. S. Local uses of Aristolochia species and content of nephrotoxic aristolochic acid 1 and 2 — a global assessment based on bibliographic sources. J. Ethnopharmacol. 125, 108–144 (2009).

pubmed: 19505558 doi: 10.1016/j.jep.2009.05.028

Chan, W. et al. Quantitation of aristolochic acids in corn, wheat grain, and soil samples collected in Serbia: identifying a novel exposure pathway in the etiology of Balkan endemic nephropathy. J. Agric. Food Chem. 64, 5928–5934 (2016).

pubmed: 27362729 doi: 10.1021/acs.jafc.6b02203

Tung, K.-K. et al. Occurrence and environmental stability of aristolochic acids in groundwater collected from Serbia: links to human exposure and Balkan endemic nephropathy. Environ. Sci. Technol. 54, 1554–1561 (2020).

pubmed: 31884786 doi: 10.1021/acs.est.9b05337

Li, W., Hu, Q. & Chan, W. Uptake and accumulation of nephrotoxic and carcinogenic aristolochic acids in food crops grown in Aristolochia clematitis-contaminated soil and water. J. Agric. Food Chem. 64, 107–112 (2016).

pubmed: 26654710 doi: 10.1021/acs.jafc.5b05089

Pavlović, N. M. et al. Possible health impacts of naturally occurring uptake of aristolochic acids by maize and cucumber roots: links to the etiology of endemic (Balkan) nephropathy. Environ. Geochem. Health 35, 215–226 (2013).

pubmed: 22851152 doi: 10.1007/s10653-012-9477-8

Lukinich-Gruia, A. T. et al. Aristolochic acid I as an emerging biogenic contaminant involved in chronic kidney diseases: a comprehensive review on exposure pathways, environmental health issues and future challenges. Chemosphere 297, 134111 (2022).

pubmed: 35231474 doi: 10.1016/j.chemosphere.2022.134111

Chan, C.-K., Tung, K.-K., Pavlović, N. M. & Chan, W. Remediation of aristolochic acid-contaminated soil by an effective advanced oxidation process. Sci. Total. Environ. 720, 137528 (2020).

pubmed: 32143041 doi: 10.1016/j.scitotenv.2020.137528

Li, W. et al. Aristolochic acids as persistent soil pollutants: determination of risk for human exposure and nephropathy from plant uptake. J. Agric. Food Chem. 66, 11468–11476 (2018).

pubmed: 30286603 pmcid: 6413692 doi: 10.1021/acs.jafc.8b04770

Wu, K. M., Farrelly, J. G., Upton, R. & Chen, J. Complexities of the herbal nomenclature system in traditional Chinese medicine (TCM): lessons learned from the misuse of Aristolochia-related species and the importance of the pharmaceutical name during botanical drug product development. Phytomedicine 14, 273–279 (2007).

pubmed: 16863692 doi: 10.1016/j.phymed.2006.05.009

Grollman, A. P. & Marcus, D. M. Global hazards of herbal remedies: lessons from Aristolochia. EMBO Rep. 17, 619–625 (2016).

pubmed: 27113747 pmcid: 5341512 doi: 10.15252/embr.201642375

Brunner, S. F. et al. Somatic mutations and clonal dynamics in healthy and cirrhotic human liver. Nature 574, 538–542 (2019).

pubmed: 31645727 pmcid: 6837891 doi: 10.1038/s41586-019-1670-9

Zlotta, A. R. et al. Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non–muscle-invasive bladder cancer. Eur. Urol. 59, 1026–1031 (2011).

pubmed: 21458152 doi: 10.1016/j.eururo.2011.03.027

Chen, C.-H. et al. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int. J. Cancer 133, 14–20 (2013).

pubmed: 23292929 doi: 10.1002/ijc.28013

Cosyns, J.-P. et al. Chinese herbs nephropathy-associated slimming regimen induces tumours in the forestomach but no interstitial nephropathy in rats. Arch. Toxicol. 72, 738–743 (1998).

pubmed: 9879812 doi: 10.1007/s002040050568

Debelle, F. D. et al. Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J. Am. Soc. Nephrol. 13, 431–436 (2002).

pubmed: 11805172 doi: 10.1681/ASN.V132431

Qiu, Q., Liu, Z. H., Chen, H. P., Yin, H. L. & Li, L. S. Long-term outcome of acute renal injury induced by Aristolochia manshuriensis Kom in rats. Acta Pharmacol. Sin. 21, 1129–1135 (2000).

pubmed: 11603288

Cui, M. Tumour induction in rats following exposure to short-term high dose aristolochic acid I. Mutagenesis 20, 45–49 (2005).

pubmed: 15644423 doi: 10.1093/mutage/gei007

Hadjiolov, D. et al. Effect of diallyl sulfide on aristolochic acid-induced forestomach carcinogenesis in rats. Carcinogenesis 14, 407–410 (1993).

pubmed: 8453716 doi: 10.1093/carcin/14.3.407

Cosyns, J.-P. et al. Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? Kidney Int. 59, 2164–2173 (2001).

pubmed: 11380818 doi: 10.1046/j.1523-1755.2001.00731.x

Kohara, A., Suzuki, T., Honma, M., Ohwada, T. & Hayashi, M. Mutagenicity of aristolochic acid in the lambda/lacZ transgenic mouse (Muta™Mouse). Mutat. Res. Genet. Toxicol. Environ. Mutagen. 515, 63–72 (2002).

doi: 10.1016/S1383-5718(01)00350-3

Li, X.-L., Guo, X.-Q., Wang, H.-R., Chen, T. & Mei, N. Aristolochic acid-induced genotoxicity and toxicogenomic changes in rodents. World J. Tradit. Chin. Med. 6, 12–25 (2020).

pubmed: 32258091 pmcid: 7110418 doi: 10.4103/wjtcm.wjtcm_33_19

Chen, Y.-Y. et al. Aristolochic acid suppresses DNA repair and triggers oxidative DNA damage in human kidney proximal tubular cells. Oncol. Rep. 24, 141–153 (2010).

pubmed: 20514455

Yu, F.-Y., Wu, T.-S., Chen, T.-W. & Liu, B.-H. Aristolochic acid I induced oxidative DNA damage associated with glutathione depletion and ERK1/2 activation in human cells. Toxicol. Vitr. 25, 810–816 (2011).

doi: 10.1016/j.tiv.2011.01.016

Nitzsche, D., Melzig, M. F. & Arlt, V. M. Evaluation of the cytotoxicity and genotoxicity of aristolochic acid I–A component of Aristolochiaceae plant extracts used in homeopathy. Environ. Toxicol. Pharmacol. 35, 325–334 (2013).

pubmed: 23434523 doi: 10.1016/j.etap.2013.01.007

Bastek, H. et al. Comparison of aristolochic acid I derived DNA adduct levels in human renal toxicity models. Toxicology 420, 29–38 (2019).

pubmed: 30940547 doi: 10.1016/j.tox.2019.03.013

Liu, X. et al. Mitochondrial dysfunction is involved in aristolochic acid I-induced apoptosis in renal proximal tubular epithelial cells. Hum. Exp. Toxicol. 39, 673–682 (2020).

pubmed: 31884831 doi: 10.1177/0960327119897099

Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941–D947 (2019).

pubmed: 30371878 doi: 10.1093/nar/gky1015

Mengs, U. Acute toxicity of aristolochic acid in rodents. Arch. Toxicol. 59, 328–331 (1987).

pubmed: 3579596 doi: 10.1007/BF00295084

Mengs, U. & Stotzem, C. D. Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology. Arch. Toxicol. 67, 307–311 (1993).

pubmed: 8368940 doi: 10.1007/BF01973700

Jiang, Z. et al. Possible role of mtDNA depletion and respiratory chain defects in aristolochic acid I-induced acute nephrotoxicity. Toxicol. Appl. Pharmacol. 266, 198–203 (2013).

pubmed: 22820421 doi: 10.1016/j.taap.2012.07.008

Dong, H. et al. Quantitative determination of aristolochic acid-derived DNA adducts in rats using

pubmed: 16611860 doi: 10.1124/dmd.105.008706

Mei, N., Arlt, V. M., Phillips, D. H., Heflich, R. H. & Chen, T. DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver. Mutat. Res. Fund. Mol. Mech. Mutagen. 602, 83–91 (2006).

doi: 10.1016/j.mrfmmm.2006.08.004

Quan, Y. et al. Assessment of nephrotoxicity of herbal medicine containing aristolochic acid in mice. Korean J. Intern. Med. 35, 400 (2020).

pubmed: 31739654 doi: 10.3904/kjim.2018.280

Arlt, V. M. et al. Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int. J. Cancer 128, 21–32 (2011).

pubmed: 20232387 doi: 10.1002/ijc.25324

Baudoux, T. et al. CD4

doi: 10.1038/s41598-018-23565-2

Zhou, L. et al. Mechanism of chronic aristolochic acid nephropathy: role of Smad3. Am. J. Physiol. Ren. Physiol. 298, F1006–F1017 (2010).

doi: 10.1152/ajprenal.00675.2009

Ye, J. et al. Aristolochic acid I aggravates renal injury by activating the C3a/C3aR complement system. Toxicol. Lett. 312, 118–124 (2019).

pubmed: 31048001 doi: 10.1016/j.toxlet.2019.04.027

Ding, Y.-J. & Chen, Y.-H. Developmental nephrotoxicity of aristolochic acid in a zebrafish model. Toxicol. Appl. Pharmacol. 261, 59–65 (2012).

pubmed: 22472514 doi: 10.1016/j.taap.2012.03.011

Chen, T. et al. Gene expression profiles distinguish the carcinogenic effects of aristolochic acid in target (kidney) and non-target (liver) tissues in rats. BMC Bioinform. 7 (Suppl. 2), S20 (2006).

doi: 10.1186/1471-2105-7-S2-S20

Grollman, A. P. & Jelaković, B. Role of environmental toxins in endemic (Balkan) nephropathy. J. Am. Soc. Nephrol. 18, 2817 (2007).

pubmed: 17942951 doi: 10.1681/ASN.2007050537

Zhou, Y. et al. Aristolochic acid causes albuminuria by promoting mitochondrial DNA damage and dysfunction in podocyte. PloS ONE 8, e83408 (2013).

pubmed: 24349506 pmcid: 3862730 doi: 10.1371/journal.pone.0083408

Romanov, V., Whyard, T. C., Waltzer, W. C., Grollman, A. P. & Rosenquist, T. Aristolochic acid-induced apoptosis and G2 cell cycle arrest depends on ROS generation and MAP kinases activation. Arch. Toxicol. 89, 47–56 (2015).

pubmed: 24792323 doi: 10.1007/s00204-014-1249-z

Correa-Rotter, R. & García-Trabanino, R. Mesoamerican nephropathy. Semin. Nephrol. 39, 263–271 (2019).

pubmed: 31054625 doi: 10.1016/j.semnephrol.2019.02.004

Wijkstrom, J. et al. Renal morphology, clinical findings, and progression rate in Mesoamerican nephropathy. Am. J. Kidney Dis. 69, 626–636 (2017).

pubmed: 28126239 doi: 10.1053/j.ajkd.2016.10.036

Gifford, F. J., Gifford, R. M., Eddleston, M. & Dhaun, N. Endemic nephropathy around the world. Kidney Int. Rep. 2, 282–292 (2017).

pubmed: 28367535 doi: 10.1016/j.ekir.2016.11.003

Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246–259 (2013).

pubmed: 23318258 pmcid: 3588146 doi: 10.1016/j.celrep.2012.12.008

Koh, G., Degasperi, A., Zou, X., Momen, S. & Nik-Zainal, S. Mutational signatures: emerging concepts, caveats and clinical applications. Nat. Rev. Cancer 21, 619–637 (2021).

pubmed: 34316057 doi: 10.1038/s41568-021-00377-7

Senkin, S. MSA: reproducible mutational signature attribution with confidence based on simulations. BMC Bioinforma. 22, 540 (2021).

doi: 10.1186/s12859-021-04450-8

Degasperi, A. et al. A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies. Nat. Cancer 1, 249–263 (2020).

pubmed: 32118208 pmcid: 7048622 doi: 10.1038/s43018-020-0027-5

Koh, G., Zou, X. & Nik-Zainal, S. Mutational signatures: experimental design and analytical framework. Genome Biol. 21, 37 (2020).

pubmed: 32059681 pmcid: 7023746 doi: 10.1186/s13059-020-1951-5

Melki, P. N., Korenjak, M. & Zavadil, J. Experimental investigations of carcinogen-induced mutation spectra: innovation, challenges and future directions. Mutat. Res. Genet. Toxicol. Env. Mutagen. 853, 503195 (2020).

doi: 10.1016/j.mrgentox.2020.503195

Zavadil, J. & Rozen, S. G. Experimental delineation of mutational signatures is an essential tool in cancer epidemiology and prevention. Chem. Res. Toxicol. 32, 2153–2155 (2019).

pubmed: 31509385 doi: 10.1021/acs.chemrestox.9b00339

Zou, X. et al. Validating the concept of mutational signatures with isogenic cell models. Nat. Commun. 9, 1744 (2018).

pubmed: 29717121 pmcid: 5931590 doi: 10.1038/s41467-018-04052-8

Wu, Y., Chua, E. H. Z., Ng, A. W. T., Boot, A. & Rozen, S. G. Accuracy of mutational signature software on correlated signatures. Sci. Rep. 12, 390 (2022).

pubmed: 35013428 pmcid: 8748538 doi: 10.1038/s41598-021-04207-6

Aristolochic acid-associated cancers: a public health risk in need of global action.

Journal

Informations de publication

Résumé

Identifiants

Substances chimiques

Types de publication

Langues

Sous-ensembles de citation

Pagination

Subventions

Informations de copyright

Références

Auteurs

Samrat Das (S)

Shefali Thakur (S)

Michael Korenjak (M)

Viktoriya S Sidorenko (VS)

Felicia Fei-Lei Chung (FF)

Jiri Zavadil (J)

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Smoking Cessation and Incident Cardiovascular Disease.

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Classifications MeSH